{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:51:57Z","timestamp":1788601917950,"version":"build-2803163510"},"reference-count":117,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The term osteomalacia (OM) refers to a series of processes characterized by altered mineralization of the skeleton, which can be caused by various disorders of mineral metabolism. OM can be genetically determined or occur due to acquired disorders, among which the nutritional origin is particularly relevant, due to its wide epidemiological extension and its nature as a preventable disease. Among the hereditary diseases associated with OM, the most relevant is X-linked hypophosphatemia (XLH), which manifests in childhood, although its consequences persist into adulthood where it can acquire specific clinical characteristics, and, although rare, there are XLH cases that reach the third or fourth decade of life without a diagnosis. Some forms of OM present very subtle initial manifestations which cause both considerable diagnosis and treatment delay. On occasions, the presence of osteopenia and fragility fractures leads to an erroneous diagnosis of osteoporosis, which may imply the prescription of antiresorptive drugs (i.e., bisphosphonates or denosumab) with catastrophic consequences for OM bone. On the other hand, some radiological features of OM can be confused with those of axial spondyloarthritis and lead to erroneous diagnoses. The current prevalence of OM is not known and is very likely that its incidence is much higher than previously thought. Moreover, OM explains part of the therapeutic failures that occur in patients diagnosed with other bone diseases. Therefore, it is essential that clinicians who treat adult skeletal diseases take into account the considerations provided in this practical review when focusing on the diagnosis and treatment of their patients with bone diseases.<\/jats:p>","DOI":"10.3390\/jcm12072714","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T01:39:26Z","timestamp":1680658766000},"page":"2714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Osteomalacia in Adults: A Practical Insight for Clinicians"],"prefix":"10.3390","volume":"12","author":[{"given":"Luis","family":"Arboleya","sequence":"first","affiliation":[{"name":"Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bra\u00f1a","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Pardo","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Loredo","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[{"name":"Rheumatology Division, Hospital Universitario Central de Asturias (HUCA), 33011 Oviedo, Spain"},{"name":"ISPA Translational Immunology Division, Biohealth Research Institute of the Principality of Asturias (ISPA), 33011 Oviedo, Spain"},{"name":"School of Medicine, Oviedo University, 33011 Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41574-022-00682-7","article-title":"Skeletal and extraskeletal disorders of biomineralization","volume":"18","author":"Collins","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-12-416015-6.00001-0","article-title":"Bone Morphology and Organization","volume":"Volume 1","author":"Burr","year":"2014","journal-title":"Basic and Applied Bone Biology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000443136","article-title":"Global Consensus Recommendations on Prevention and Management of Nutritional Rickets","volume":"85","author":"Munns","year":"2016","journal-title":"Horm. Res. Paediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11914-017-0383-y","article-title":"Nutritional Rickets and Osteomalacia in the Twenty-first Century: Revised concepts, public health, and prevention strategies","volume":"15","author":"Uday","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00247-012-2532-x","article-title":"Rickets: Part I","volume":"43","author":"Shore","year":"2013","journal-title":"Pediatr. Radiol."},{"key":"ref_6","unstructured":"Feldman, D., Pike, J., and Glorieux, F. (2004). Vitamin D, Elsevier. [2nd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Figueres, L., Beck-Cormier, S., Beck, L., and Marks, J. (2021). The complexities of organ crosstalk in phosphate homeostasis: Time to put phosphate sensing back in the lime light. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115701"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/0004563214521399","article-title":"Phosphate homeostasis and disorders","volume":"51","author":"Manghat","year":"2014","journal-title":"Ann. Clin. Biochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1172\/JCI3208","article-title":"Rapid downregulation of rat renal Na\/P(i) cotransporter in response to parathyroid hormone involves microtubule rearrangement","volume":"104","author":"Lotscher","year":"1999","journal-title":"J. Clin. Invest."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/sj.ki.5001813","article-title":"Proximal tubular handling of phosphate: A molecular perspective","volume":"70","author":"Forster","year":"2006","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/ki.2008.643","article-title":"Latest findings in phosphate homeostasis","volume":"75","author":"Prie","year":"2009","journal-title":"Kidney Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/jbmr.5650040407","article-title":"Parabiosis suggests a humoral factor is involved in X-linkedhypophosphatemia in mice","volume":"4","author":"Meyer","year":"1989","journal-title":"J. Bone Miner. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199406093302304","article-title":"Brief report: Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia","volume":"330","author":"Cai","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"ADHR Consortium (2000). Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet., 26, 345\u2013348.","DOI":"10.1038\/81664"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fendo.2015.00154","article-title":"Endocrine FGFs: Evolution, physiology, pathophysiology, and pharmacotherapy","volume":"6","author":"Itoh","year":"2015","journal-title":"Front. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1359\/jbmr.080417","article-title":"Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23","volume":"23","author":"Yamazaki","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_19","first-page":"17","article-title":"FGF23 and associated disorders of phosphate wasting","volume":"17","author":"Gohil","year":"2019","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00774-015-0698-7","article-title":"Pathogenesis and diagnostic criteria for rickets and osteomalacia\u2014Proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society","volume":"33","author":"Fukumoto","year":"2015","journal-title":"J. Bone Miner. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jsbmb.2019.01.004","article-title":"Spot the silent sufferers: A call for clinical diagnostic criteria for solar and nutritional osteomalacia","volume":"188","author":"Uday","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_22","unstructured":"Pope, T.L. (2008). Imaging of the Musculoskeletal System, 1st ed, Saunders."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hodler, J., Kubik-Huc, R.A., and von Schulthess, G.K. (2021). Musculoskeletal Diseases 2021\u20132024, Springer.","DOI":"10.1007\/978-3-030-71281-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","article-title":"Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia","volume":"16","author":"Collins","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","first-page":"402","article-title":"Raquitismo y osteomalacia nutricionales e inducidos por f\u00e1rmacos","volume":"Volume 60","author":"Favus","year":"2007","journal-title":"Primer on the Metabolic Bone Disorders and Disorders of Mineral Metabolism. ASBMR"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 processing in fibrous dysplasia","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","first-page":"e10554","article-title":"Vitamin D: A critical regulator of intestinal physiology","volume":"5","author":"Christakos","year":"2021","journal-title":"J. Bone Miner. Res. Plus"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bouillon, R., Antonio, L., and Olarte, O.R. (2022). Calcifediol (25OH Vitamin D3) deficiency: A risk factor from early to old age. Nutrients, 14.","DOI":"10.3390\/nu14061168"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/er.2018-00126","article-title":"Skeletal and extraskeletal actions of Vitamin D: Current evidence and outstanding questions","volume":"1","author":"Bouillon","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_30","first-page":"e10447","article-title":"Osteomalacia and vitamin D status: A clinical update 2020","volume":"21","author":"Minisola","year":"2020","journal-title":"J. Bone Miner. Res. Plus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.00015.2012","article-title":"Gastric acid, calcium absorption, and their impact on bone health","volume":"93","author":"Kopic","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1515\/cclm-2022-1267","article-title":"Assessing vitamin D metabolism-four decades of experience","volume":"61","author":"Herrmann","year":"2023","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ajcn\/nqab048","article-title":"Serum 25-hydroxyvitamin D requirements to prevent nutritional rickets in Nigerian children on a low-calcium diet. A multivariable reanalysis","volume":"114","author":"Sempos","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1159\/000527011","article-title":"Rickets, vitamin D, and Ca\/P metabolism","volume":"95","author":"Miller","year":"2022","journal-title":"Horm. Res. Paediatr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3177\/jnsv.59.257","article-title":"The solar exposure time required for vitamin D3 synthesis in the human body estimated by numerical simulation and observation in Japan","volume":"59","author":"Miyauchi","year":"2013","journal-title":"J. Nutr. Sci. Vitaminol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-08-0818","article-title":"Incidence and prevalence of nutritional and hereditary rickets in southern Denmark","volume":"160","author":"Gram","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: Prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: A retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41419-022-04969-5","article-title":"Function of PHEX mutations p.Glu145* and p.Trp749Arg in families with X-linked hypophosphatemic rickets by the negative regulation mechanism on FGF23 promoter transcription","volume":"13","author":"Gan","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_40","first-page":"674","article-title":"Disorders of phosphate homeostasis","volume":"Volume 88","author":"Bilezikian","year":"2019","journal-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ASBMR"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00431-007-0662-1","article-title":"What\u2019s new in hypophosphataemic rickets?","volume":"167","author":"Pettifor","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","article-title":"Burden of disease associated with X-linked hypophosphataemia in adults: A systematic literature review","volume":"32","author":"Seefried","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00198-022-06318-w","article-title":"Physical function and physical activity in adults with X-linked hypophosphatemia G","volume":"33","author":"Orlando","year":"2022","journal-title":"Osteoporos. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","article-title":"Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fbrous dysplasia","volume":"11","author":"Watts","year":"2016","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00198-020-05537-3","article-title":"Physical function in UK adults with osteogenesis imperfecta: A cross-sectional analysis of the RUDY study","volume":"32","author":"Orlando","year":"2021","journal-title":"Osteoporos. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"680598","DOI":"10.3389\/fmed.2021.680598","article-title":"Comparative analysis of clinical and imaging features of osteomalacia and spondyloarthritis","volume":"8","author":"Zhao","year":"2021","journal-title":"Front. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1210\/jcem-54-2-307","article-title":"The efficacy of vitamin D2 and oral phosphorus therapy in X-linked hypophosphatemic rickets and osteomalacia","volume":"54","author":"Lyles","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/BF01213343","article-title":"Therapeutics of X-linked hypophosphatemic rickets","volume":"7","author":"Latta","year":"1993","journal-title":"Pediatr. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1210\/jc.2011-1319","article-title":"Approach to the hypophosphatemic patient","volume":"97","author":"Imel","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1359\/jbmr.090509","article-title":"Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia","volume":"24","author":"Aono","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcph.1950","article-title":"Population pharmacokinetics and pharmacodynamics of Burosumab in adult and pediatric patients with X-linked Hypophosphatemia","volume":"62","author":"Lee","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of Burosumab, a monoclonal antibody to FGF23, in children with X-Linked Hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eprac.2022.09.007","article-title":"Phosphatonins: From discovery to therapeutics","volume":"29","author":"Kritmetapak","year":"2022","journal-title":"Endocr. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: A randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"ref_56","unstructured":"The European Medicines Agency (2022, December 02). European Public Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/crysvita-epar-publicassessment-report_en.pdf."},{"key":"ref_57","unstructured":"(2022, December 02). Ficha T\u00e9cnica de Burosumab (Crysvita\u00ae). Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1171262001\/FT_1171262001.pdf."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"bvaa151","DOI":"10.1210\/jendso\/bvaa151","article-title":"X-Linked Hypophosphatemia: A new era in management","volume":"4","author":"Dahir","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"ref_60","first-page":"33","article-title":"Osteomalacia with Looser\u2019s nodes (Milkman\u2019s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years","volume":"16","author":"McCance","year":"1947","journal-title":"Q. J. Med."},{"key":"ref_61","first-page":"554","article-title":"Rickets following bone tumor","volume":"14","author":"Prader","year":"1959","journal-title":"Helv. Paediatr. Acta"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2012.11.040","article-title":"Oncogenic osteomalacia\u2014Hypophosphataemic spectrum from \u201cbenignancy\u201d to \u201cmalignancy\u201d","volume":"53","author":"Chiam","year":"2013","journal-title":"Bone"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","article-title":"Tumor-induced osteomalacia: A systematic clinical review of 895 cases","volume":"111","author":"Bosman","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gupta, A., Kandasamy, D., Sharma, R., Damle, N., Goyal, A., Goyal, A., Agarwal, S., and Dharmashaktu, Y. (2023). Imaging characteristics of phosphaturic mesenchymal tumors. Acta Radiol., 2841851231160086.","DOI":"10.1177\/02841851231160086"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: A retrospective analysis of 144 cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00774-021-01250-1","article-title":"Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23","volume":"39","author":"Ito","year":"2021","journal-title":"J. Bone Miner. Metab."},{"key":"ref_69","first-page":"bnac026","article-title":"Tumor-induced osteomalacia: A comprehensive review","volume":"44","author":"Minisola","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","article-title":"Tumor-induced osteomalacia","volume":"20","author":"Florenzano","year":"2017","journal-title":"Bone Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/jbmr.4702","article-title":"Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia","volume":"37","author":"Hartley","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"bvac181","DOI":"10.1210\/jendso\/bvac181","article-title":"Utility of multimodality aproach including systemic FGF23 venous sampling in localizing phosphaturic mesenchymal tumors","volume":"7","author":"Kato","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/HP.0000000000001425","article-title":"Patient release and instructions for Lutetium Dotatate Radiopharmaceutical Therapy","volume":"121","author":"Underwood","year":"2021","journal-title":"Health Phys."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing Burosumab efficacy and safety in patients with Tumor-Induced Osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-022-06516-6","article-title":"Long-term use of burosumab for the treatment of tumor-induced osteomalacia","volume":"34","author":"Crotti","year":"2023","journal-title":"Osteoporos. Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/joim.13593","article-title":"Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia","volume":"293","author":"Minisola","year":"2023","journal-title":"J. Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jbmr.4620","article-title":"Clinical challenges in diagnosis, tumor localization and treatment of Tumor-Induced Osteomalacia: Outcome of a retrospective surveillance","volume":"37","author":"Hidaka","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543784.2021.1864320","article-title":"Infigratinib (BGJ398): An investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma","volume":"30","author":"Botrus","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e10661","DOI":"10.1002\/jbm4.10661","article-title":"Infigratinib reduces Fibroblast Growth Factor 23 (FGF23) and increases blood phosphate in Tumor-Induced Osteomalacia","volume":"6","author":"Hartley","year":"2022","journal-title":"JBMR Plus"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/qjmed\/hct258","article-title":"Drug-induced renal Fanconi syndrome","volume":"107","author":"Hall","year":"2014","journal-title":"QJM Int. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00467-013-2512-x","article-title":"The effects of sodium valproate on the renal function of children with epilepsy","volume":"29","author":"Knights","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"ref_82","first-page":"301","article-title":"Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: Could different components of aristolochic acids cause a different type of Chinese herb nephropathy?","volume":"53","author":"Tanaka","year":"2000","journal-title":"Clin. Nephrol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/jat.4118","article-title":"Relationship between osteoid formation and iron deposition induced by chronic cadmium exposure in ovariectomized rats","volume":"41","author":"Wako","year":"2021","journal-title":"J. Appl. Toxicol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3389\/fonc.2020.00779","article-title":"Electrolyte disorders induced by antineoplastic drugs","volume":"10","author":"Verzicco","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2021.07.003","article-title":"Hypophosphatemia in acute liver failure of a broad range of etiologies is associated with phosphaturia without kidney damage or phosphatonin elevation","volume":"238","author":"Zechner","year":"2021","journal-title":"Transl. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clgc.2021.07.013","article-title":"A Phase II, randomized, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases","volume":"19","author":"Matsubara","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/2249-4863.192338","article-title":"Impact of antiepileptic drugs on bone health: Need for monitoring, treatment, and prevention strategies","volume":"5","author":"Arora","year":"2016","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00277-020-04351-5","article-title":"Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: A single clinic retrospective study","volume":"100","author":"Regidor","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2010.30.8387","article-title":"Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed\/refractory solid tumors or myelodysplastic syndrome: A Children\u2019s Oncology Group Phase I Consortium report","volume":"29","author":"Berg","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1634\/theoncologist.2020-0127","article-title":"A phase II trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases","volume":"25","author":"Xu","year":"2020","journal-title":"Oncologist"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2200191","DOI":"10.1200\/PO.22.00191","article-title":"Cobimetinib plus Vemurafenib in patients with Colorectal Cancer with BRAF mutations: Results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"6","author":"Klute","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2016-0101","article-title":"Benefit-Risk Summary of Crizotinib for the treatment of patients with ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: A systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11060-019-03194-z","article-title":"Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE\/NCCTG)","volume":"143","author":"Jaeckle","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.26831","article-title":"A Phase II Study of combination Daunorubicin, Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in patients newly diagnosed with Acute Myeloid Leukemia with KIT Expression","volume":"98","author":"Tibes","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/hepr.13588","article-title":"Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma","volume":"51","author":"Terashima","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cam4.5044","article-title":"A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results","volume":"12","author":"Attia","year":"2022","journal-title":"Cancer Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10637-013-9999-7","article-title":"A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer","volume":"32","author":"Schelman","year":"2014","journal-title":"Investig. New Drugs"},{"key":"ref_100","first-page":"e3947","article-title":"Partial Fanconi syndrome induced by Ifosfamide","volume":"11","author":"Das","year":"2019","journal-title":"Cureus"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Jebali, M., Elaidi, R., Brizard, M., Fouque, J., Takouchop, C., Sabatier, B., Oudard, S., and Medioni, J. (2017). Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. BMC Cancer, 17.","DOI":"10.1186\/s12885-016-2993-7"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"979983","DOI":"10.3389\/fimmu.2022.979983","article-title":"Drug-induced Fanconi syndrome in patients with kidney allograft transplantation","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2021.12.015","article-title":"Zoledronic acid-associated Fanconi syndrome in patients with cancer","volume":"80","author":"Mount","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/dtb.2021.235083rep","article-title":"Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis","volume":"59","author":"Bagger","year":"2021","journal-title":"Drug Ther. Bull."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e250647","DOI":"10.1136\/bcr-2022-250647","article-title":"Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy","volume":"15","author":"Nachankar","year":"2022","journal-title":"BMJ Case Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"103770","DOI":"10.1016\/j.amsu.2022.103770","article-title":"Prevalence and correlates of hypophosphatemia among type 2 diabetic patients attending the National Center for Diabetes, Endocrinology and Genetics (NCDEG)","volume":"78","author":"Rashed","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M","article-title":"Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission","volume":"25","author":"Ragab","year":"1970","journal-title":"Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00223-020-00765-5","article-title":"Clinical and radiological characterization of patients with immobilizing and progressive stress fractures in Methotrexate Osteopathy","volume":"108","author":"Rolvien","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/0961203319841434","article-title":"Stress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy","volume":"28","author":"Rolvien","year":"2019","journal-title":"Lupus"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","article-title":"Intravenous Iron-Induced Hypophosphatemia: An emerging syndrome","volume":"38","author":"Glaspy","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.26100","article-title":"Parenteral iron therapy and phosphorus homeostasis: A review","volume":"96","author":"Ganz","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_114","first-page":"586","article-title":"Fanconi s\u00edndrome and other tubule proximal disorders","volume":"Volume 48","author":"Feehally","year":"2019","journal-title":"Comprehensive Clinical Nephrology"},{"key":"ref_115","first-page":"59","article-title":"Renal and bone toxicity with the use of Tenofovir: Understanding at the end","volume":"18","author":"Casado","year":"2016","journal-title":"AIDS Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-61779-163-5_22","article-title":"Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment","volume":"755","author":"Kohler","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Sano, T., Kawaguchi, T., Ide, T., Amano, K., Kuwahara, R., Arinaga-Hino, T., and Torimura, T. (2021). Tenofovir Alafenamide rescues renal tubules in patients with Chronic Hepatitis B. Life, 11.","DOI":"10.3390\/life11030263"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:16Z","timestamp":1760123416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":117,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072714"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072714","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}